Get the Daily Brief
Latest Biotech News
M&A: Neurocrine’s $2.9B Soleno acquisition to expand Prader-Willi therapy
Neurocrine Biosciences announced it will buy Soleno Therapeutics for $2.9 billion to add Vykat XR (diazoxide choline) to its rare-disease portfolio. The deal price is $53 per share in cash,...
ADC and drug development setbacks: Lipocine’s rapid-onset postpartum depression miss and trial divergence
Lipocine added another clinical setback as its oral postpartum depression program failed to meet its primary endpoint in individuals with postpartum depression. BioCentury’s clinical report...
Oncology mechanism research: mitochondrial function and immune control in antitumor response
A St. Jude-led study in Science reports that tumors can suppress immune “gatekeeper” dendritic cells by reprogramming their mitochondrial metabolism. In preclinical mouse models, restoring...
Precision oncology diagnostics: whole-genome sequencing for routine cancer care
Dutch researchers argued in Nature Medicine that whole-genome sequencing (WGS) should move toward routine use in cancer care, either for biomarker-guided therapy selection or for clarifying tumor...
Rare disease and translational strategy: clinical and funding signals around new platforms
Researchers at Vanderbilt Center for Antibody Therapeutics entered an option agreement with Saravir Biopharma to develop human monoclonal antibodies designed to treat and prevent measles...
Oncology drug delivery innovation: 3D-printed carriers for tumor-local drug release
University of Mississippi researchers reported a 3D-printed spanlastic drug-delivery approach targeting tumors with localized anticancer dosing. The strategy combines nanotechnology with additive...
Clinical trial design and data platforms: AI-structured protocol development at BMS
Bristol Myers Squibb said it is partnering with Faro Health to use AI for clinical trial protocol design. The multiyear effort is intended to accelerate study design and drafting by converting...
Funding and corporate buildout: Stipple emerges with $100M for antibody-drug conjugate target discovery
Stipple Bio raised $100 million in a Series A to advance STP-100, an antibody-drug conjugate (ADC) targeting an undisclosed antigen, and to expand its Pointillist discovery platform for precision...
FDA regulatory speed-up for early drug development
The FDA is proposing an “optional, risk-based” expedited Investigational New Drug pathway designed to move certain experimental drugs into human testing faster, aligning with a framework the...
M&A: Neurocrine moves to buy Soleno for PWS therapy
Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics, valuing the deal at $53 per share in cash. The purchase adds Soleno’s Vykat XR (diazoxide choline), the only...
Biotech funding: Stipple Bio emerges with $100M for novel oncology targets
Stipple Bio launched with a $100 million Series A financing to advance STP-100, an antibody-drug conjugate (ADC) aimed at an undisclosed target, while also building its Pointillist discovery...
Neural diagnostics: Multimodal MRI plus machine learning targets earlier Parkinson’s detection
New research highlights a multimodal machine-learning strategy for earlier Parkinson’s disease detection by combining quantitative susceptibility mapping (QSM) with magnetic resonance spectroscopy...
Oncology immunotherapy mechanism: restoring dendritic-cell mitochondrial function boosts checkpoint responses
A St. Jude Children’s Research Hospital team reported in Science that tumors can disable dendritic cells by reprogramming mitochondrial metabolism, weakening the cells’ ability to initiate...
Precision oncology testing: Netherlands data supports routine whole-genome sequencing in cancer care
Researchers in the Netherlands argued in Nature Medicine that whole-genome sequencing (WGS) should be incorporated into routine cancer care, proposing it can identify clinically actionable...
Regenerative/biomarker tech: MethylScan low-cost cfDNA methylome test for multi-disease screening
UCLA scientists disclosed an affordable blood test, MethylScan, designed to detect multiple cancers and liver disorders simultaneously by analyzing cell-free DNA methylation patterns. The approach...
Regenerative engineering: Mayo Clinic nanotherapy crosses the blood–brain barrier in glioblastoma models
Mayo Clinic researchers developed an experimental dual-drug nanotherapy intended to penetrate the blood–brain barrier and deliver treatment directly to glioblastoma tumors. The preclinical...
Neurodegeneration deal fallout: Takeda terminates Denali partnership over restructuring
Takeda ended its long-running co-development partnership with Denali Therapeutics, returning full rights to DNL593 ahead of the asset’s next clinical steps amid Takeda restructuring. The...
Regulatory designation: FDA grants Fast Track to TRI-611 in ALK-positive NSCLC
The FDA granted Fast Track designation to TRI-611 for ALK-positive non-small cell lung cancer, positioning the program for potential expedited interaction with the agency during development....
Neurocrine’s $2.9B move into Prader-Willi hyperphagia therapy
Neurocrine Biosciences agreed to buy Soleno Therapeutics in a $2.9 billion cash deal, paying $53 per share—a 34% premium to Soleno’s prior close. The acquisition adds Soleno’s Prader-Willi...
FDA proposes accelerated early-phase path; Takeda exits Denali dementia program
The FDA’s 2027 budget proposal outlined a potential new “optional, risk-based” expedited Investigational New Drug pathway that would allow some experimental drugs to enter U.S. Phase 1 testing...